Walden Group Healthcare M&A Blog

  • Catalent to Acquire Paragon Bioservices for $1.2b

    Catalent, Inc., a $2.46b provider of delivery technologies for drugs, biologics, and consumer and animal health products, is buying Paragon Bioservices, Inc., a developer of viral vectors for gene therapies. The deal Complements Catalent's biologics business. Paragon engages in the production and purification of therapeutic proteins, monoclonal...
    Read More
  • Smith & Nephew to Buy Osiris Therapeutics

    Smith & Nephew plc (LSE:SN, NYSE:SNN), a $4.9b maker of orthopedic, wound management, sports medicine and trauma & extremities products, is acquiring Osiris Therapeutics, Inc., a provider of regenerative medicine products, including skin, bone graft and articular cartilage substitutes. The deal accelerates S&N's wound management...
    Read More
  • Medtronic to Acquire EPIX Therapeutics

    Medtronic plc (NYSE: MDT), a $29.95b manufacturer of cardio-vascular, orthopedic, spinal and other medical devices., is buying EPIX Therapeutics, Inc. (formerly Advanced Cardiac Therapeutics), a maker of a catheter-based, temperature-controlled cardiac ablation systems. The acquisition expands Medtronic's cardiac ablation portfolio. EPIX...
    Read More
  • Abbott Laboratories to Acquire Cephea Valve Technologies

    Abbott Laboratories, a $20.4b global developer of diagnostics, medical devices, nutritionals and branded generic pharmaceuticals is buying Cephea Valve Technologies, Inc, a developer of a less-invasive heart valve replacement technology for mitral valve disease. The deal Strengthens Abbott's in structural heart therapies. Cephea's artificial...
    Read More
  • Bristol-Myers Squibb Buying Celgene for $74b

    Bristol-Myers Squibb Company, a $20.8b global biopharma company is buying Celgene Corporation, a $13b developer of therapies for cancer and inflammatory diseases. The Deal strengthens Bristol-Myers in oncology, cardiovascular disease, immunology and inflammation. Celgene is known for its blockbuster Thalomid and Revlimid cancer drugs. The...
    Read More